Trial Profile
A 28-Day, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Anti-Inflammatory Effect and Steady-State Pharmacokinetics of SB-681323 (7.5 mg) in Subjects With Coronary Heart Disease (CHD) Undergoing Elective Percutaneous Coronary Interventions (PCI).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Dilmapimod (Primary)
- Indications Atherosclerosis; Coronary artery disease
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors GSK
- 15 Oct 2008 Actual start date changed from Feb 2006 to Mar 2006 as reported by ClinicalTrials.gov.
- 14 Oct 2008 Status changed to completed as reported by ClinicalTrials.gov.
- 25 Jun 2007 Status change from recruiting to in progress.